Patents Expiring in December 2033
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | 10,857,162 | ⤷ Try for Free | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | 10,251,896 | ⤷ Try for Free | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | 9,872,865 | ⤷ Try for Free | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | 11,071,742 | ⤷ Try for Free | Y | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | 8,912,210 | ⤷ Try for Free | Y | Y | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
